New hope for rare disease: expanded access to experimental drug for A-T patients
NCT ID NCT07380165
First seen Feb 02, 2026 · Last updated May 25, 2026 · Updated 13 times
Summary
This program provides an experimental drug, levacetylleucine, to people with Ataxia-Telangiectasia (A-T), a rare and serious genetic disease that affects movement and immune function. It is for patients who cannot join clinical trials and have no other good treatment options. The goal is to offer access to a potential therapy while gathering more information about its effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATAXIA-TELANGIECTASIA (A-T) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.